Antibacterial activity of phytochemicals isolated from Erythrina zeyheri against vancomycin-resistant enterococci and their combinations with vancomycin

被引:32
|
作者
Sato, M
Tanaka, H
Oh-Uchi, T
Fukai, T
Etoh, H
Yamaguchi, R
机构
[1] Asahi Univ, Sch Dent, Dept Oral Pathol, Gifu 5010296, Japan
[2] Meijo Univ, Fac Pharm, Dept Nat Prod Chem, Tempaku Ku, Nagoya, Aichi 4688503, Japan
[3] Toho Univ, Sch Pharmaceut Sci, Chiba 2748510, Japan
[4] Shizuoka Univ, Fac Agr, Lab Marine Biochem Sci, Shizuoka 4228529, Japan
[5] Asahi Univ, Sch Dent, Inst Radioisotope, Gifu 5010296, Japan
关键词
VRE; MRSA; erybraedin A; eryzerin C; vancomycin; FIC index;
D O I
10.1002/ptr.1556
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Six phytochemicals were isolated from the roots of Eiythrina zeyheri (Leguminosae) by repeated silica gel column chromatography using various eluting solvents. Extensive spectroscopic studies revealed that all were isoflavonoids. The antibacterial activity of the six compounds against vancomycin-resistant enterococci (VRE) was estimated by determining the minimum inhibitory concentration (MIC). Of the six isoflavonoids, erybraedin A ((6aR, 11aR)-3,9-dihydroxy-4,10-di(gamma,gamma-dimethylallyl)pterocarpan) exhibited the highest growth inhibitory potency against VRE with an MIC value of 1.56-3.13 mug/mL, followed by eryzerin C ((3R)-7,2',4'-trihydroxy-6,8-di(gamma,gamma-dimethylailyl)isoflavan) (MIC 6.25 mug/mL). These compounds also inhibited the growth of methicillin-resistant Staphylococcus aureus (MRSA) at 3.13-6.25 mug/mL. The antibacterial effects of the two compounds against VRE and MRSA were based on bacteriostatic action. When erybraedin A or eryzerin C was combined with vancomycin, the fractional inhibitory concentration (FIC) index against VRE ranged from 0.5306 to 1.0 and from 0.5153 to 0.75, respectively. The combinations also showed FIC indices of 0.6125-1.0 against MRSA. The results indicate that, depending on the case, both compounds act either synergistically or additively with vancomycin against VRE and MRSA. Erybraedin A and eryzerin C show evidence of being potent phytotherapeutic agents against infections caused by VRE and MRSA. Copyright (C) 2004 John Wiley Sons, Ltd.
引用
收藏
页码:906 / 910
页数:5
相关论文
共 50 条
  • [21] Antibacterial activity of stilbene oligomers against vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA) and their synergism with antibiotics
    Kinki University, Faculty of Agriculture, 3327-204 Nakamachi, Nara-shi, Nara 631-8505, Japan
    不详
    Biocontrol Sci., 2007, 1 (7-14): : 7 - 14
  • [22] Screening for vancomycin-resistant enterococci: results of a survey in Stockholm
    Fang, Hong
    Nord, Carl Erik
    Ullberg, Mans
    APMIS, 2010, 118 (05) : 413 - 417
  • [23] Vancomycin-resistant enterococci in shellfish, unchlorinated waters, and chicken
    Wilson, IG
    McAfee, GG
    INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY, 2002, 79 (03) : 143 - 151
  • [24] Optimizing therapy for vancomycin-resistant enterococci (VRE)
    Linden, Peter K.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 28 (06) : 632 - 645
  • [25] Vancomycin-resistant enterococci (VRE): a reason to isolate?
    Vehreschild, Maria J. G. T.
    Haverkamp, Miriam
    Biehl, Lena M.
    Lemmen, Sebastian
    Faetkenheuer, Gerd
    INFECTION, 2019, 47 (01) : 7 - 11
  • [26] EPIDEMIOLOGICAL ASPECTS OF THE OCCURRENCE OF VANCOMYCIN-RESISTANT ENTEROCOCCI
    Oliveira, Adriana Cristina
    Bettcher, Ledna
    REVISTA DA ESCOLA DE ENFERMAGEM DA USP, 2010, 44 (03) : 725 - 731
  • [27] Vancomycin-resistant enterococci (VRE): a reason to isolate?
    Maria J. G. T. Vehreschild
    Miriam Haverkamp
    Lena M. Biehl
    Sebastian Lemmen
    Gerd Fätkenheuer
    Infection, 2019, 47 : 7 - 11
  • [28] Vancomycin-resistant enterococci: 15 years and counting
    Chavers, LS
    Moser, SA
    Benjamin, WH
    Banks, SE
    Steinhauer, JR
    Smith, AM
    Johnson, CN
    Funkhouser, E
    Chavers, LP
    Stamm, AM
    Waites, KB
    JOURNAL OF HOSPITAL INFECTION, 2003, 53 (03) : 159 - 171
  • [29] Emergence of vancomycin-resistant enterococci from vancomycin-susceptible enterococci in hospitalized patients under antimicrobial therapy
    Janice, Jessin
    Wagner, Theresa Maria
    Olsen, Karina
    Hegstad, Joachim
    Hegstad, Kristin
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2024, 36 : 116 - 122
  • [30] In vitro activity of LY333328, a new glycopeptide, against extracellular and intracellular vancomycin-resistant enterococci
    Al-Nawas, B
    Swantes, J
    Shah, PM
    INFECTION, 2000, 28 (04) : 214 - 218